TheranosticTrials.org

Clinical Trial · NCT06461182

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

Overview

This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.

Sponsor

Unknown Organization

Phase

Phase 2

Contacts

Cheng Ling Yang, B.Rad. (CONTACT)

androgyny@kfsyscc.org

+886 28970011

Yu Yi Huang, MD (CONTACT)

yuyi@kfsyscc.org

+886 28970011

ClinicalTrials.gov

NCT06461182

Drug / Compound

Pentixafor

Isotope(s):
Target(s):
  • CXCR4
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • Able to lie flat for at least 30 minutes.
  • The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL/SLL, mantle cell lymphoma.
  • Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group.
  • Signing the subject consent form.
  • The timing of F-18-FDG usage in this trial follows the "Lymphoma Treatment Principles" of our institution.
  • ECOG grade 0-2.

Exclusion

  • Inability to undergo the necessary PET scan procedure
  • Concurrent or previous diagnosis of malignancies other than lymphoma
  • Severe renal impairment (eGRF\< 30ml/min)
  • Severe medical conditions (severe disabilities, mental disorders)
  • Pregnant woman
  • Known or suspected allergy to radiopharmaceuticals